GLP-1 Drugs and Vision Loss: What the FDA Warning Means

The FDA has warned that GLP-1 medications may increase the risk of non-arteritic anterior ischemic optic neuropathy, a rare condition that can cause sudden, potentially permanent vision loss in one eye. The agency will require manufacturers to add the risk to the drugs’ warning labels. Eye specialists say the complication remains extremely rare, and advise patients not to panic but to discuss concerns with their healthcare providers.